Denali Therapeutics Inc. DNLI Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s change in accrued liabilities?
- Denali Therapeutics Inc. (DNLI) reported change in accrued liabilities of -$22.4M in Q1 2026.
- How has Denali Therapeutics Inc.'s change in accrued liabilities changed year-over-year?
- Denali Therapeutics Inc.'s change in accrued liabilities decreased by 131.2% year-over-year, from -$9.69M to -$22.4M.
- What is the long-term trend for Denali Therapeutics Inc.'s change in accrued liabilities?
- Over 2 years (2022 to 2025), Denali Therapeutics Inc.'s change in accrued liabilities has grown at a -79.4% compound annual growth rate (CAGR), from $10.92M to $465K.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.